Ark. judge affirms $181 million in legal fees

(AP)—An Arkansas judge says Johnson & Johnson must pay $181 million in fees to attorneys who successfully argued that the pharmaceutical company committed Medicaid fraud in the marketing of its antipsychotic drug Risperdal.

Pulaski County Tim Fox ruled Thursday that Arkansas taxpayers should not foot the bill in the lawsuit filed by the state's attorney general. Last year, a jury found that Johnson & Johnson, through its Janssen Pharmaceuticals subsidiary, had committed Medicaid fraud and violated the state's deceptive trade practices act.

Johnson & Johnson had argued that legal fees of $2.2 million to $3.8 million would be appropriate. A Janssen spokeswoman tells the Arkansas Democrat-Gazette (is.gd/Qf85x4 ) that the company maintains it did not violate the state's Medicaid fraud law and that no legal fees should have been ordered.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Report: J&J will pay $2.2B in Risperdal settlement

Jul 20, 2012

(AP) — Johnson & Johnson has agreed to pay as much as $2.2 billion to resolve an investigation into its marketing of the anti-psychotic drug Risperdal, according to a published report.

Merck pays J&J $500mn in drug row settlement

Apr 15, 2011

Merck said Friday it has agreed to pay fellow US pharmaceutical giant Johnson & Johnson $500 million to end a two-year tussle over profit-sharing deals for two anti-inflammatory drugs.

Danish Genmab inks $1.1 bn deal with Johnson & Johnson

Aug 30, 2012

Danish pharmaceutical group Genmab said Thursday it had reached a deal worth up to $1.1 billion (876 million euros) with US drug giant Johnson & Johnson for the rights to the cancer treatment Daratumumab.

Johnson & Johnson plans to buy Dutch vaccine group

Sep 17, 2010

US cosmetics and pharmaceutical giant Johnson & Johnson said on Friday it intended to acquire a Dutch vaccine maker Crucell which is active in developing countries for about 1.75 billion euros.

Public Citizen: State drug fraud cases on the rise

Sep 27, 2012

(AP)—A consumer advocacy group is reporting that pharmaceutical companies have paid more than $30 billion to state and federal governments to settle allegations of fraud over the last 20 years.

Recommended for you

Study recalculates costs of combination vaccines

Apr 17, 2014

One of the most popular vaccine brands for children may not be the most cost-effective choice. And doctors may be overlooking some cost factors when choosing vaccines, driving the market toward what is actually a more expensive ...

Drug watchdog urges vigilance in cancer drug theft

Apr 17, 2014

Europe's medicine watchdog urged doctors Thursday to be vigilant in administering the cancer drug Herceptin, vials of which had been stolen in Italy and tampered with before being sold back into the supply chain.

User comments